Incyte Pulls Parsaclisib Files As FDA Takes Foot Off Accelerator
Was Seeking Accelerated Approval For PI3K inhibitor For Lymphoma
Executive Summary
After discussions with the FDA, which has made its feelings clear on accelerated approvals, Incyte has concluded it cannot complete the confirmatory trials in lymphomas that would be needed on parsaclisib in time to make them worth their while.
You may also be interested in...
Incyte Streamlines Pipeline After Difficult Q1
The mid-sized pharma company has a blockbuster in Jakafi, but analysts are doubtful about its plans to build on that base across its now slimmed-down pipeline.
Incyte’s Jakafi Flunks In Phase III Myelofibrosis Study As Loss Of Exclusivity Nears
The company said it would discontinue the Phase III LIMBER-304 trial in patients who had inadequate response to Jakafi when an analysis indicated the study would not reach its primary endpoint.
Despite FDA Setback, MEI’s Zandelisib Could Still Break PI3K Curse
MEI/Kyowa Kirin will no longer seek accelerated approval based on a single-arm study as the FDA is calling for Phase III data due to growing conservatism regarding the PI3K class.